Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Preferred Stock Liabilities (2019 - 2020)

Harmony Biosciences Holdings (HRMY) has disclosed Preferred Stock Liabilities for 2 consecutive years, with $434.0 million as the latest value for Q2 2020.

  • Quarterly Preferred Stock Liabilities changed N/A to $434.0 million in Q2 2020 from the year-ago period, while the trailing twelve-month figure was $434.0 million through Jun 2020, changed N/A year-over-year, with the annual reading at $411.3 million for FY2019, N/A changed from the prior year.
  • Preferred Stock Liabilities hit $434.0 million in Q2 2020 for Harmony Biosciences Holdings, up from $411.3 million in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $434.0 million in Q2 2020 to a low of $400.9 million in Q3 2019.